Kinetic Study of Human Pharmacokinetics in Normal Renal Function, and Renal Insufficiency Subject of Polyethylene Glycol Loxenatide (PEX168)(Open, Non-randomized, Parallel-group)
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2016
At a glance
- Drugs PEG loxenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Jiangsu Hansoh Pharmaceutical
- 25 Jan 2016 Planned end date changed from 1 Dec 2015 to 1 May 2016, as reported by ClinicalTrials.gov.
- 25 Jan 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.
- 15 Jun 2015 New trial record